Kinesin family member 14 in human oral cancer: A potential biomarker for tumoral growth  by Miyamoto, Isao et al.
Biochemistry and Biophysics Reports 3 (2015) 26–31Contents lists available at ScienceDirectBiochemistry and Biophysics Reportshttp://d
2405-58
n Corr
Medicin
Fax: þ8
nn Cor
E-m
uzawakjournal homepage: www.elsevier.com/locate/bbrepKinesin family member 14 in human oral cancer: A potential
biomarker for tumoral growth
Isao Miyamoto a, Atsushi Kasamatsu b,nn, Masanobu Yamatoji b, Dai Nakashima a,
Kengo Saito a, Morihiro Higo b, Yosuke Endo-Sakamoto b, Masashi Shiiba c,
Hideki Tanzawa a,b, Katsuhiro Uzawa a,b,n
a Department of Oral Science, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
b Department of Dentistry and Oral-Maxillofacial Surgery, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
c Department of Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japana r t i c l e i n f o
Article history:
Received 12 May 2015
Received in revised form
10 July 2015
Accepted 14 July 2015
Available online 15 July 2015
Keywords:
Kinesin family member 14 (KIF14)
Oral squamous cell carcinoma
Tumoral size
Cell-cycle arrest
G2/M phasex.doi.org/10.1016/j.bbrep.2015.07.008
08/& 2015 The Authors. Published by Elsevier
esponding author at: Department of Oral
e, Chiba University, 1-8-1 Inohana, Chuo-
1 43 226 2300.
responding author.
ail addresses: kasamatsua@faculty.chiba-u.jp (
@faculty.chiba-u.jp (K. Uzawa).a b s t r a c t
Kinesin family member 14 (KIF14), a microtubule-based motor protein, plays an important role in
chromosomal segregation, congression, and alignment. Considerable evidence indicates that KIF14 is
involved in cytokinesis, although little is known about its role in oral squamous cell carcinomas (OSCCs).
In the current study, we functionally and clinically investigated KIF14 expression in patients with OSCC.
Quantitative reverse transcriptase–polymerase chain reaction and immunoblotting analyses were used
to assess the KIF14 regulatory mechanism in OSCC. Immunohistochemistry (IHC) was performed to
analyze the correlation between KIF14 expression and clinical behavior in 104 patients with OSCC. A
KIF14 knockdown model of OSCC cells (shKIF14 cells) was used for functional experiments. KIF14 ex-
pression was up-regulated signiﬁcantly (Po0.05) in OSCCs compared with normal counterparts in vitro
and in vivo. In addition, shKIF14 cells inhibited cellular proliferation compared with control cells by cell-
cycle arrest at the G2/M phase through up-regulation of G2 arrest-related proteins (p-Cdc2 and cyclin
B1). As expected, IHC data from primary OSCCs showed that KIF14-positive patients exhibited sig-
niﬁcantly (Po0.05) more larger tumors compared with KIF14-negative patients. The current results
suggest for the ﬁrst time that KIF14 is an indicator of tumoral size in OSCCs and that KIF14 might be a
potential therapeutic target for development of new treatments for OSCCs.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Kinesins are a family of the ATP-dependent motor proteins that
travel unidirectionally along microtubule tracks to fulﬁll their
many roles in intracellular transport or cell division [1–3]. Kinesins
have so far been classiﬁed into 14 subfamilies (kinesin-1 family–
kinesin-14 family) by phylogenetic analysis of the motor domain
[1,4] and are additionally composed of 45 kinesin superfamily
proteins (KIFs) [1,5]. KIFs reportedly transport organelles or par-
ticipate in signal transduction, but mainly participate in cell mi-
tosis, particularly in spindle formation, chromosomal and nuclear
movement, and cytokinesis [5].B.V. This is an open access article u
Science, Graduate School of
ku, Chiba 260-8670, Japan.
A. Kasamatsu),Previous studies also have indicated that KIFs play critical roles
in several malignancies, including tumoral development and pro-
gression [1,2,4–10]. Among them, KIF14 protein is localized at the
spindle midzone (the area formed between retreating chromo-
somes as they segregate toward the spindle poles in anaphase)
and the midbody (the cytoplasmic bridge that connects two
daughter cells at the end of cytokinesis in telophase) [11,12], and is
essential for cytokinesis and chromosome segregation. KIF14 has
genomic gain at 1q31.3–1q32.1 with overexpressed gene levels in
multiple cancers, i.e., breast, retinoblastoma, liver, renal, lung,
laryngeal, and ovarian cancers and synovial sarcoma [13–28].
However, the relationship between overexpression of KIF14 and
clinical behavior of oral squamous cell carcinoma (OSCC) has not
yet been clariﬁed.
In the current study, we report that KIF14 expression in OSCCs
is functionally and clinically linked to tumoral size in vitro and
in vivo and show that KIF14 is closely related to the cell cycle.
Therefore, KIF14 might be a potential therapeutic target for OSCCs.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Ethics statement
The Ethical Committee of the Graduate School of Medicine,
Chiba University approved the study protocol (approval number,
236); the study was performed in accordance with the tenets of
the Declaration of Helsinki. All patients provided written informed
consent before participating in this research.
2.2. OSCC-derived cell lines and tissue specimens
Human OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, KOSC-2,
Ca9-22, Ho-1-N-1, Ho-1-u-1, and SAS) were obtained from the
Human Science Research Resources Bank (Osaka, Japan) or the
RIKEN BioResource Center (Ibaraki, Japan). Primary cultured hu-
man normal oral keratinocytes (HNOKs) were obtained from three
healthy donors and served as normal controls [29,30]. All cells
were grown in Dulbecco's modiﬁed Eagle medium (Sigma-Aldrich
Co, St. Louis, MO, USA) supplemented with 10% fetal bovine serum
(Sigma) and 50 units/ml penicillin and streptomycin (Sigma).
Clinicopathologic staging was determined by the TNM classiﬁca-
tion of the International Union against Cancer [31].
2.3. Preparation of cDNA and protein
Total RNA and protein were isolated as described previously
[28,29].
2.4. mRNA expression analysis
Real-time quantitative reverse transcriptase–polymerase chain
reaction (qRT–PCR) was conducted as described previously
[28,29]. Primers and universal probes were designed using the
Universal Probe Library Assay Design Center (Roche Diagnostics
GmbH), which speciﬁes the most suitable set. The primer se-
quences used for qRT–PCR were: KIF14, forward, 5′-
CCTGTCTTTTTGCTTATGGTCAG-3′; reverse, 5′-TCTTCACTAAATCC-
CATCATCG-3′; and universal probe #21, and the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), forward, 5′-AGCCA-
CATCGCTCAGACAC-3′; reverse, 5′-GCCCAATACGACCAAATCC-3′;
and universal probe #60.
2.5. Immunoblotting analysis
Immunoblotting analysis was performed as described pre-
viously [28,29]. The antibodies were rabbit anti-KIF14 polyclonal
antibody (Cat. no. A300-912A, Bethyl Laboratories, Montgomery,
AL, USA), mouse anti-GAPDH monoclonal antibody (Cat. no. sc-
32233, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-
phospho-CDC2 polyclonal antibody (Cat. no. sc-101654, Santa Cruz
Biotechnology), and rabbit anti-cyclin B1 polyclonal antibody (Cat.
no. 12231, Cell Signaling Technology, Danvers, MA, USA).
2.6. IHC
IHC using the primary antibody was performed as previously
described [32,33]. To quantify the KIF14 protein expression in
those components, we used the previously described IHC scoring
system [32,33]. To determine the cutoff points of KIF14 IHC scores,
we analyzed the IHC scores of 104 patients using the receiver
operating characteristic (ROC) curve. Cases with a score following
over 95.0 (Youden Index and ROC curve for tumoral tissue) were
considered KIF14-positive. Two independent pathologists from
Chiba University Hospital, neither of whom had knowledge of the
patients' clinical status, made these judgments.2.7. Transfection with shRNA plasmid
A total of 1105 cells from the Ho-1-N-1 and SAS cell lines
were transfected with 10 ng/ml KIF14 shRNA (shKIF14) or 10 ng/ml
control shRNA (shMock) vectors (Santa Cruz Biotechnology) using
1.25 ml Lipofectamine index LTX and 0.5 ml Plus Reagents (Invitro-
gen, Carlsbad, CA, USA). The stable shKIF14 and shMock cells were
isolated using a culture medium containing 1 mg/ml puromycin
(Santa Cruz Biotechnology).
2.8. Cellular growth
To evaluate the effect of KIF14 knockdown on cellular growth,
we analyzed cellular growth in the shKIF14 and shMock cells.
These cells were seeded in 6 cm plates at a density of 1104 vi-
able cells. A cellular growth assay was performed as described
previously [28,29].
2.9. Cell-cycle analysis
To synchronize cells at the G0/G1 or G2/M transition, the cells
were cultured in serum free media for 48 h or treated with 200 ng/
ml nocodazole (Sigma) for 12 h [34,35]. Cell-cycle analysis was
performed as described previously [28].
2.10. Statistical analysis
In comparisons of KIF14 expression levels, statistical sig-
niﬁcance was evaluated using the Mann–Whitney U-test. Re-
lationships between the KIF14-IHC scores and clinicopathological
proﬁles were evaluated using the Mann–Whitney U-test. Po0.05
was considered signiﬁcant. The data are expressed as the
mean7standard error of the mean (SEM).3. Results
3.1. Evaluation of KIF14 expression in OSCC-derived cell lines
To investigate the expression status of KIF14, we performed
qRT–PCR and immunoblotting analyses using eight OSCC-derived
cell lines (HSC-2, HSC-3, HSC-4, KOSC-2, Ca9-22, Ho-1-N-1, Ho-1-
u-1, and SAS) and HNOKs. KIF14 mRNA was up-regulated sig-
niﬁcantly (Po0.05) in all OSCC-derived cell lines compared with
the HNOKs (Fig. 1A). Representative results of immunoblotting
analysis are shown in Fig. 1B. The KIF14 protein expression was up-
regulated signiﬁcantly (Po0.05) in all OSCC-derived cell lines
compared with the HNOKs.
3.2. Evaluation of KIF14 expression in primary OSCCs
Representative IHC results for KIF14 protein in primary OSCCs
and adjacent normal oral tissue are shown in Fig. 2A and B, re-
spectively. Strong KIF14 immunoreactivity was detected in the
nucleus of OSCC tissues, whereas the normal tissues showed al-
most negative immunostaining. We analyzed the KIF14 protein
expression in primary OSCCs from 104 patients using the IHC
scoring system [36,37]. The KIF14 IHC scores in OSCCs and ad-
jacent normal oral tissues ranged from 70 to 230 (median, 150)
and 10–135 (median, 65), respectively. The IHC scores in primary
OSCCs were signiﬁcantly (Po0.05) higher than in normal oral
tissues (Fig. 2C). To determine an optimal cutoff point of the
identiﬁed IHC scores, we used the Youden Index and ROC curve
analyses. In addition to the data from the Youden Index (sensi-
tivity, 79.8%; speciﬁcity, 90.4%, Po0.05), ROC curve analysis
showed that the cutoff value was 95.0 (Fig. 2D, E).
AB
Fig. 1. Evaluation of KIF14 expression in OSCC-derived cell lines. (A) Quantiﬁcation
of KIF14 mRNA expression in OSCC-derived cellular lines by qRT-PCR analysis.
Signiﬁcant up-regulation of KIF14mRNA is seen in eight OSCC-derived cellular lines
compared with the HNOKs (Po0.05, Mann–Whitney U-test). Data are expressed as
the means7SEM of triplicate results. (B) Immunoblotting analysis of KIF14 protein
in the OSCC-derived cell lines and HNOKs. KIF14 protein expression is up-regulated
in the OSCC-derived cell lines compared with that in the HNOKs. Densitometric
KIF14 protein data are normalized to GAPDH protein levels.
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Since frequent up-regulation of KIF14 occurred in OSCC-derived
cells (Fig. 1), the OSCC-derived cells (Ho-1-N-1 and SAS) were
transfected with KIF14 shRNA and shMock as controls. To conﬁrm
the efﬁciency of shKIF14 transfection, we performed qRT–PCR and
immunoblotting analyses (Fig. 3A, B). KIF14 mRNA expression inA
B
C
Fig. 2. Evaluation of KIF14 expression in primary OSCCs. (A, B) Representative IHC resu
Strong KIF14 immunoreactivity is detected in the nuclei of primary OSCCs; normal o
expression in primary OSCCs (n¼104) and the normal counterparts. The KIF14 IHC scores
(median, 150), respectively. KIF14 protein expression levels in OSCCs are signiﬁcantly (Po
analysis shows that the optimal cutoff point is 95.0. (E) ROC curve analysis shows thatshKIF14 cells was signiﬁcantly (Po0.05) lower than in the shMock
cells (Fig. 3A). The KIF14 protein level in the shKIF14 cells also
decreased compared with the shMock cells (Fig. 3B).
3.4. Cellular proliferation of KIF14 knockdown cells
To evaluate the effect of KIF14 knockdown on cellular growth,
we performed a cellular proliferation assay (Fig. 3C). We found a
signiﬁcant (Po0.05) decrease in cellular growth in shKIF14 cells
compared with shMock cells. Therefore, the assays showed that
KIF14 knockdown decreased cellular growth.
3.5. Cell-cycle analysis of KIF14 knockdown cells
To investigate the mechanism by which KIF14 is related to
cellular proliferation, we performed cell-cycle analysis of KIF14
knockdown cells using Ho-1-N-1 and SAS. The percentage of the
shKIF14 cells in the G2/M phase was signiﬁcantly (Po0.05) higher
than in the Mock cells (Fig. 4A). We also assessed the expression
levels of the G2 arrest-related proteins, p-Cdc2 and cyclin B1. As
expected, these were up-regulated in shKIF14 cells (Fig. 4B). These
results indicated that shKIF14 cells inhibited cellular proliferation
by cell-cycle arrest at the G2/M phase.
3.6. Correlation between KIF14 expression and clinical classiﬁcations
in primary OSCCs
The correlations between the clinicopathological characteristics
of the patients with OSCC and the status of KIF14 protein ex-
pression using the IHC scoring system are shown in Table 1.
Among the clinical parameters, signiﬁcant (P¼0.019) differences
in tumoral size in KIF14-positive patients with OSCC were seen
compared with KIF14-negative patients.4. Discussion
The current study provided the ﬁrst evidence that KIF14 over-
expression occurs in OSCCs and is positively correlated withD
E
lts for KIF14 protein in primary OSCCs and normal oral tissue (scale bars, 10 μm).
ral tissues show almost negative immunostaining. (C) The state of KIF14 protein
for normal oral tissues and OSCCs range from 10 to 135 (median, 65) and 70 to 230
0.05, Mann–Whitney's U test) higher than in normal oral tissues. (D) Youden Index
the optimal cutoff point is 95.0.
A C
B
Fig. 3. Establishment of KIF14 knockdown cells and cellular proliferation of KIF14 knockdown cells. (A) qRT-PCR shows that KIF14mRNA expression in the shKIF14 cells (Ho-
1-N-1-and SAS-derived transfectants; 2 clones each) is signiﬁcantly (Po0.05, Mann–Whitney U-test) lower than in the shMock cells. (B) Immunoblotting analysis shows that
the KIF14 protein levels in shKIF14 cells (Ho-N-1- and SAS-derived transfectants; 2 clones each) also have decreased markedly compared with that in the shMock cells. (C) To
determine the effect of shKIF14 on cellular proliferation, shKIF14 and shMock cells were seeded in six-well plates at a density of 1104 viable cells/well. Both transfectants
were counted on seven consecutive days. The cellular growth of shKIF14 cells (Ho-1-N-1- and SAS-derived transfectants; 2 clones each) are signiﬁcantly (Po0.05, Mann–
Whitney U test) inhibited compared with the shMock cells after 72 (Ho-1-N-1) and 96 (SAS) hours. The results are expressed as the means7SEM of values from three assays.
A B
Fig. 4. Cell-cycle analysis of KIF14 knockdown cells. (A) Flow cytometric analysis was performed to investigate the cell cycle in shKIF14 and shMock cells. The percentage of
the G2/M phase in shKIF14 cells (Ho-N-1- and SAS-derived transfectants; 2 clones each) has increased markedly compared with the shMock cells (Po0.05, Mann–Whitney
U-test). (B) shKIF14 cells show up-regulation of p-Cdc2 and cyclin B1 (Ho-N-1- and SAS-derived transfectants; 2 clones each) compared with shMock cells (Po0.05, Mann–
Whitney U test).
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with lymph node metastasis, stage, and grade [38,39]. Therefore,
we assumed that KIF14 may have different functions in difference
cancer types. In addition, our KIF14 knockdown experiments
showed that KIF14 controlled cellular proliferation by arresting
cell-cycle progression at the G2/M phase, suggesting that KIF14
plays a signiﬁcant role in tumoral size in human OSCCs.
Genomic ampliﬁcations, 1q31.3–1q32.1, are observed in several
types of cancer, leading to overexpression of KIF14 mRNA and
protein [13–24,28]. In addition, overexpressed KIF14 mRNA and
protein were reported as potential prognostic markers and ther-
apeutic targets in retinoblastoma and breast, lung, and ovarian
cancers [15,16,24,28,40]. In contrast, low expression of KIF14 wasassociated with poor overall survival in patients with lung ade-
nocarcinoma [38]. Therefore, KIF14 plays pivotal roles in devel-
opment and progression of several types of cancers.
Transient KIF14 knockdown cervical cancer cells showed sig-
niﬁcantly decreased proliferative and colony forming capabilities
[39,41]; however, the reasons for the cellular behaviors are un-
known. Our previous study reported that KIF4A is closely related
to the spindle assembly checkpoint (SAC) [36]; therefore, we
speculated here that KIF14 is associated with cytokinesis and has a
critical role in cell-cycle arrest [11,12]. Consistent with our hy-
pothesis, our KIF14 knockdown models showed cell-cycle arrest at
the G2/M phase by activation of G2 arrest-related proteins. Inter-
estingly, KIF14 did not participate in the SAC (data not shown),
Table 1
Correlation between KIF14 expression and clinical classiﬁcation in OSCCs.
Clinical classiﬁcation Total Results of immunostaining no. of
patients (%)
P value
KIF14 negative KIF14 positive
Age at surgery (years)
o60 18 9 (50) 9 (50) 0.382
≧60, o70 24 8 (35) 16 (65)
≧70 62 23 (37) 39 (63)
Gender
Male 65 24 (37) 41 (63) 0.438
Female 39 16 (41) 23 (59)
T-primary tumor
T1 6 4 (67) 2 (33) 0.019n
T2 54 25 (46) 29 (54)
T3 20 6 (30) 14 (70)
T4 24 5 (22) 19 (78)
N-regional lymph
node
Negative 62 22 (35) 40 (65) 0.121
Positive 42 18 (44) 24 (56)
Stage
I 5 3 (60) 2 (40) 0.563
II 42 17 (37) 25 (63)
III 19 6 (32) 13 (68)
IV 38 14 (39) 24 (61)
Vascular invasion
Negative 85 36 (43) 49 (57) 0.439
Positive 19 4 (21) 15 (79)
Histopathologic type
Well 64 24 (38) 40 (62) 0.512
Moderately 33 13 (40) 20 (60)
Poorly 7 3 (43) 4 (57)
Tumoral site
Gingiva 30 15 (50) 15 (50) 0.471
Tongue 58 20 (35) 38 (65)
Buccal mucosa 10 4 (40) 6 (60)
Oral ﬂoor 6 1 (17) 5 (83)
n Po0.05 was considered signiﬁcant.
I. Miyamoto et al. / Biochemistry and Biophysics Reports 3 (2015) 26–3130whereas KIF14 and KIF4A are similar kinesin superfamily proteins.
Radiation therapy is a major adjuvant treatment for patients
with OSCC. The cells in the G2/M phase are highly radiosensitive,
whereas the cells in the G0 and G1/S phases have low radio-
sensitivity. Since KIF14 knockdown led to cell-cycle arrest at the
G2/M phase, combination radiation therapy with KIF14 inhibition
seems critical for patients with OSCC.
In the current study, we found that KIF14 plays an important
role in OSCC growth; therefore, KIF14 expression is likely to be a
biomarker of proliferation and a potential therapeutic target for
development of anticancer therapy for OSCC.Conﬂict of interest statement
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